Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chitosan vs Ankaferd vs Tranexamic Acid for Hemostasis in Dental Extraction
NCT06457360Phase 1Completed
- Sponsor
- The British University in Egypt
- Start
- Nov 2023
- Primary completion
- Jan 2024
- Modality
- Injectable Hydrogels, Implantable Hydrogels, Biodegradable Polymers
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of chitosan and Ankaferd Blood Stopper in postextraction hemorrhage (PEH) (3 arms), sponsored by The British University in Egypt. Primary endpoint: Hemostatic effect assessment at 30 minutes. Started Nov 2023; status: completed.
02
Drugs
chitosanAnkaferd Blood Stopper
03
Conditions
postextraction hemorrhage (PEH)
Beyond the preview
Go deeper on NCT06457360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06457360.